Biosensors 2012, 2(4), 377-387; doi:10.3390/bios2040377
Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor
Po-Yuan Lin 1, Kai-Lun Cheng 2, James D. McGuffin-Cawley 1, Fuh-Sheng Shieu 2, Anna C. Samia 3, Sanjay Gupta 4
, Matthew Cooney 5, Cheryl L. Thompson 6 and Chung Chiun Liu 7,*
, Matthew Cooney 5, Cheryl L. Thompson 6 and Chung Chiun Liu 7,*
1
Department of Materials Science & Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
2
Department of Materials Science & Engineering, National Chung Hsing University, No. 250, Guoguang Road, Nan District, Taichung City 402, Taiwan
3
Department of Chemistry, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
4
Department of Urology, University Hospital Case Medical Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
5
Division of Hematology/Oncology, University Hospital Case Medical Center, 10900 Euclid Avenue, Cleveland, OH 44106, USA
6
Department of Family Medicine, University Hospital Case Medical Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
7
Department of Chemical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
*
Author to whom correspondence should be addressed.
Received: 3 August 2012 / Revised: 29 August 2012 / Accepted: 24 September 2012 / Published: 26 September 2012
(This article belongs to the Special Issue Nano and Micro DNA/RNA Sensors)
Abstract
Although still commonly used in clinical practice to screen and diagnose prostate cancer, there are numerous weaknesses of prostate-specific antigen (PSA) testing, including lack of specificity and the inability to distinguish between aggressive and indolent cancers. A promising prostate cancer biomarker, alpha-methylacyl-CoA racemase (AMACR), has been previously demonstrated to distinguish cancer from healthy and benign prostate cells with high sensitivity and specificity. However, no accurate clinically useful assay has been developed. This study reports the development of a single use, disposable biosensor for AMACR detection. Human blood samples were used to verify its validity, reproducibility and reliability. Plasma samples from 9 healthy males, 10 patients with high grade prostatic intraepithelial neoplasia (HGPIN), and 5 prostate cancer patients were measured for AMACR levels. The average AMACR levels in the prostate cancer patients was 10 fold higher (mean(SD) = 0.077 (0.10)) than either the controls (mean(SD) = 0.005 (0.001)) or HGPIN patients (mean(SD) = 0.004 (0.0005)). At a cutoff of between 0.08 and 0.9, we are able to achieve 100% accuracy in separating prostate cancer patients from controls. Our results provide strong evidence demonstrating that this biosensor can perform as a reliable assay for prostate cancer detection and diagnosis. View Full-TextKeywords:
alpha-methylacyl-CoA racemase (AMACR); prostate cancer; biosensor; electrochemical; nanoparticles
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Lin, P.-Y.; Cheng, K.-L.; McGuffin-Cawley, J.D.; Shieu, F.-S.; Samia, A.C.; Gupta, S.; Cooney, M.; Thompson, C.L.; Liu, C.C. Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor. Biosensors 2012, 2, 377-387.
Related Articles
Article Metrics
Comments
[Return to top]
Biosensors
EISSN 2079-6374
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert